Trial Profile

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung : a Randomized Non Comparative Phase II Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HTERT peptide vaccine-Invectys (Primary) ; Nivolumab (Primary) ; Docetaxel
Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms Optim-UCPVax

Most Recent Events

22 Jan 2025 Status changed from active, no longer recruiting to completed.
26 Jul 2023 Planned primary completion date changed from 30 Sep 2025 to 1 Sep 2023.
26 Jul 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com